Advertisement
Screener

Keros Therapeutics, Inc. (KROS) Increase (Decrease) in Prepaid Expense and Other Assets

2.8 / 5 stars · 68/120 Roast Me

Keros Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets

Keros Therapeutics, Inc. (KROS) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$15.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-03

  • Keros Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $497.00K, a 90.25% decline year-over-year.
  • Keros Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$15.67M.
  • Keros Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$141.00K, a 102.69% decline year-over-year.
  • Keros Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$4.43M.
  • Keros Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$4.02M, a 139.33% decline from fiscal 2024.
  • Keros Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $10.22M, a 10.05% increase from fiscal 2023.
  • Keros Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $9.28M, a 179.55% increase from fiscal 2022.
  • Keros Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $3.32M, a 114.53% increase from fiscal 2021.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 month
2026-06-30$497.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
-$15.18M
10-Q · filed 2026-08-03
-$15.32M
derived: sum of 3 quarters · filed 2026-08-03
-$19.75M
derived: sum of 4 quarters · filed 2026-08-03
2026-03-31-$15.67M
10-Q · filed 2026-05-14
-$15.81M
derived: sum of 2 quarters · filed 2026-05-14
-$20.25M
derived: sum of 3 quarters · filed 2026-05-14
-$15.15M
derived: sum of 4 quarters · filed 2026-08-03
2025-12-31-$141.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
-$4.58M
derived: sum of 2 quarters · filed 2026-03-04
$525.00K
derived: sum of 3 quarters · filed 2026-08-03
-$4.02M
10-K · filed 2026-03-04
2025-09-30-$4.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$666.00K
derived: sum of 2 quarters · filed 2026-08-03
-$3.88M
10-Q · filed 2025-11-05
$1.37M
derived: sum of 4 quarters · filed 2026-08-03
2025-06-30$5.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
$557.00K
10-Q · filed 2026-08-03
$5.80M
derived: sum of 3 quarters · filed 2026-08-03
-$70.00K
derived: sum of 4 quarters · filed 2026-08-03
2025-03-31-$4.54M
10-Q · filed 2026-05-14
$703.00K
derived: sum of 2 quarters · filed 2026-05-14
-$5.17M
derived: sum of 3 quarters · filed 2026-05-14
$1.20M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31$5.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
-$627.00K
derived: sum of 2 quarters · filed 2026-03-04
$5.74M
derived: sum of 3 quarters · filed 2026-03-04
$10.22M
10-K · filed 2026-03-04
2024-09-30-$5.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$493.00K
derived: sum of 2 quarters · filed 2025-11-05
$4.97M
10-Q · filed 2025-11-05
$4.43M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$6.37M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
$10.84M
10-Q · filed 2025-08-06
$10.30M
derived: sum of 3 quarters · filed 2025-08-06
$14.56M
derived: sum of 4 quarters · filed 2025-08-06
2024-03-31$4.48M
10-Q · filed 2025-05-06
$3.94M
derived: sum of 2 quarters · filed 2025-05-06
$8.20M
derived: sum of 3 quarters · filed 2025-05-06
$9.69M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31-$539.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$3.72M
derived: sum of 2 quarters · filed 2025-02-26
$5.21M
derived: sum of 3 quarters · filed 2025-02-26
$9.28M
10-K · filed 2025-02-26
2023-09-30$4.26M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$5.75M
derived: sum of 2 quarters · filed 2024-11-06
$9.82M
10-Q · filed 2024-11-06
$10.09M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$1.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
$5.56M
10-Q · filed 2024-08-07
$5.83M
derived: sum of 3 quarters · filed 2025-02-26
$5.55M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$4.07M
10-Q · filed 2024-05-08
$4.34M
derived: sum of 2 quarters · filed 2025-02-26
$4.06M
derived: sum of 3 quarters · filed 2025-02-26
$8.16M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$270.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
-$17.00K
derived: sum of 2 quarters · filed 2025-02-26
$4.08M
derived: sum of 3 quarters · filed 2025-02-26
$3.32M
10-K · filed 2025-02-26
2022-09-30-$287.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
$3.81M
derived: sum of 2 quarters · filed 2023-11-06
$3.05M
10-Q · filed 2023-11-06
$1.72M
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30$4.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
$3.34M
10-Q · filed 2023-08-07
$2.01M
derived: sum of 3 quarters · filed 2024-02-28
$2.53M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31-$764.00K
10-Q · filed 2023-05-04
-$2.09M
derived: sum of 2 quarters · filed 2024-02-28
-$1.57M
derived: sum of 3 quarters · filed 2024-02-28
$1.85M
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31-$1.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
-$806.00K
derived: sum of 2 quarters · filed 2024-02-28
$2.62M
derived: sum of 3 quarters · filed 2024-02-28
$1.55M
10-K · filed 2024-02-28
2021-09-30$521.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$3.95M
derived: sum of 2 quarters · filed 2022-11-03
$2.88M
10-Q · filed 2022-11-03
$2.12M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30$3.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$2.35M
10-Q · filed 2022-08-04
$1.60M
derived: sum of 3 quarters · filed 2022-08-04
$374.00K
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$1.07M
10-Q · filed 2022-05-05
-$1.83M
derived: sum of 2 quarters · filed 2022-05-05
-$3.05M
derived: sum of 3 quarters · filed 2022-05-05
-$418.00K
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31-$756.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09
-$1.98M
derived: sum of 2 quarters · filed 2022-03-09
$653.00K
derived: sum of 3 quarters · filed 2022-03-09
$1.47M
10-K · filed 2022-03-09
2020-09-30-$1.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$1.41M
derived: sum of 2 quarters · filed 2021-11-04
$2.23M
10-Q · filed 2021-11-04
$2.19M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30$2.63M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$3.45M
10-Q · filed 2021-08-05
$3.42M
derived: sum of 3 quarters · filed 2021-08-05
$3.41M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$816.00K
10-Q · filed 2021-05-06
$785.00K
derived: sum of 2 quarters · filed 2021-05-06
$778.00K
derived: sum of 3 quarters · filed 2021-05-06
$640.00K
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31-$31.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
-$38.00K
derived: sum of 2 quarters · filed 2021-03-25
-$176.00K
derived: sum of 3 quarters · filed 2021-03-25
-$1.89M
10-K · filed 2021-03-25
2019-09-30-$7.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
-$145.00K
derived: sum of 2 quarters · filed 2020-11-10
-$1.86M
10-Q · filed 2020-11-10
2019-06-30-$138.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13
-$1.85M
10-Q · filed 2020-08-13
2019-03-31-$1.72M
10-Q · filed 2020-05-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73